Last updated: 18 July 2019 at 12:04pm EST

Bioventures Ltd Novartis Net Worth




The estimated Net Worth of Bioventures Ltd Novartis is at least $263 Tisíc dollars as of 25 March 2014. Bioventures Novartis owns over 182,590 units of Akebia Therapeutics stock worth over $262,930 and over the last 11 years Bioventures sold AKBA stock worth over $0.

Bioventures Novartis AKBA stock SEC Form 4 insiders trading

Bioventures has made over 1 trades of the Akebia Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Bioventures bought 182,590 units of AKBA stock worth $3,104,030 on 25 March 2014.

The largest trade Bioventures's ever made was buying 182,590 units of Akebia Therapeutics stock on 25 March 2014 worth over $3,104,030. On average, Bioventures trades about 182,590 units every 0 days since 2014. As of 25 March 2014 Bioventures still owns at least 182,590 units of Akebia Therapeutics stock.

You can see the complete history of Bioventures Novartis stock trades at the bottom of the page.



What's Bioventures Novartis's mailing address?

Bioventures's mailing address filed with the SEC is 131 FRONT STREET, , HAMILTON, D0, HM 12.

Insiders trading at Akebia Therapeutics

Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter a Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.



What does Akebia Therapeutics do?

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.



What does Akebia Therapeutics's logo look like?

Akebia Therapeutics Inc. logo

Complete history of Bioventures Novartis stock trades at Akebia Therapeutics

Datum
#
Společnost
Osoba
Trans.
Transakce
Počet akcií Cena za akcii Celková cena Počet akcií po Zdroj
25 Mar 2014 Bioventures Ltd Novartis
10% vlastník
Koupě 182,590 $17.00 $3,104,030
25 Mar 2014
182,590


Akebia Therapeutics executives and stock owners

Akebia Therapeutics executives and other stock owners filed with the SEC include: